Blood purification involves removal of blood from a patient’s body with the help of tubing, extracorporeal cleaning using a device and returning it to the patient’s blood circulation system. For the purpose of analysis, the report segments the global market based on product type, indication, end user, and region. The report provides information about the various types of blood purification devices and consumables used during blood purification treatment. In addition, it provides details about the use of blood purification equipment in various indication such as sepsis, renal diseases, and other diseases such as hepatic failures, drug intoxication, acute pancreatitis, and infectious diseases among others. It further outlines the particulars about the major end users of blood purification equipment, including hospitals and clinics, dialysis centers and other end users such as ambulatory surgical centers, homecare, universities and research institutes. Moreover, it stipulates revenue generated through the sale of blood purification equipment across North America, Europe, Asia-Pacific, and LAMEA.

The global AI in healthcare market is estimated to grow at a CAGR of 49.8% from 2020 - 2027. Key factors that are driving growth of the market are rising application of artificial intelligence (AI) in healthcare, growing investment in ai healthcare startups and increasing cross-industry partnerships and collaborations are anticipated to drive the market. However, the dearth of skilled ai workforce and imprecise regulatory guidelines for medical software is hampering the growth of the market.

The global AI in healthcare market is highly fragmented in nature. The market comprises various emerging and established companies, such as General Electric Company, Medtronic plc, and Allscripts Healthcare Solutions, Inc. Moreover, the global companies hold 40.56% cumulatively in the global AI in healthcare market. The emerging companies vary significantly in their product offerings. The following table represents the emerging companies across various AI-enabled healthcare applications.

On January 8, 2020, the pathogen of severe unexplained viral pneumonia was identified. This was sequenced to be the new coronavirus 2019 (2019-nCoV). On February 12, 2020, the International Committee on Taxonomy of Viruses named it 2019-nCoV, which was officially named SARS-CoV-2. The World Health Organization (WHO) eventually declared the disease caused by SARS-CoV-2 coronavirus disease in 2019 (COVID-19). This virus has affected more than 100 million people and killed millions, causing difficulty breathing.

血液肿瘤领域，利妥昔单抗、伊马替尼在我国长达近二十年的市场教育及指南背书下患者用药渗透率相对较高，近年来在医保对接、类似物上市、集采降价/预期集采以及新品上市等因素的冲击下，整体市场增速放缓，也为同类型非优产品设定价格天花板，但对于仿制药/类似药替代下已获批国产企业存在结构性机会；此外耐药后、更优效的新一代药物逐步登台，并在医保对接、用药经济性、市场教育等取得阶段性成就，市场快速扩增。

2021 一季度医药板块多数公司业绩弹性得到释放，建议投资人重点关注一季报高增长品种。受疫情影响，去年一季度医药板块大部分公司业
绩受损，今年业务逐渐恢复至正常增长水平，将出现较大幅度的反弹性增长。具体来看，CXO、医疗服务、部分生物制品、医院端处方药，以及医疗器械中2020 年受疫情影响较严重的子行业（如手术产业链、IVD 中的非新冠检测等）今年一季度实现较快增长。